Background/Aims: Monocarboxylate transporter 8 (MCT8) is essential for thyroid hormone (TH) transport in the brain. Mutations in MCT8 are associated with the Allan-Herndon-Dudley syndrome (AHDS), characterized by severe psychomotor retardation and altered serum thyroid parameters. Here we report two novel mutations in MCT8 and discuss the clinical findings. Case Report and Results: We describe 4 males with AHDS from two unrelated families varying in age from 1.5 to 11 years. All 4 patients presented with typical clinical signs of AHDS, including severe psychomotor retardation, axial hypotonia, lack of speech, diminished muscle mass, increased muscle tone, hyperreflexia, myopathic facies, high T3, low T4 and rT3, and normal/mildly elevated TSH levels. Comparison of patients at different ages suggests the progressive nature of AHDS. Genetic analyses identified a novel missense MCT8 mutation (p.G495A) in family 1 and a 2.8-kb deletion comprising exons 3 and 4 in family 2. Functional analysis of p.G495A revealed impaired TH transport varying from 20 to 85% depending on the cell context. Conclusion: Here we report 4 AHDS patients in unrelated Turkish families harboring novel MCT8 mutations. Despite the widely different mutations, the clinical phenotypes are very similar and findings support the progressive nature of AHDS.

Keywords:
Allan-Herndon-Dudley syndrome, Thyroid hormone, Monocarboxylate transporter 8, Psychomotor retardation, Brain development
1.
Schwartz CE, May MM, Carpenter NJ, Rogers RC, Martin J, Bialer MG, et al: Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 gene. Am J Hum Genet 2005;77:41-53.
2.
Allan W, Herndon CN, Dudley FC: Some examples of the inheritance of mental deficiency: apparently sex-linked idiocy and microcephaly. Am J Mental Defic 1944;48:325-334.
3.
Friesema EC, Ganguly S, Abdalla A, Manning Fox JE, Halestrap AP, Visser TJ: Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biol Chem 2003;278:40128-40135.
4.
Friesema EC, Grueters A, Biebermann H, Krude H, von Moers A, Reeser M, et al: Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet 2004;364:1435-1437.
5.
Dumitrescu AM, Liao XH, Best TB, Brockmann K, Refetoff S: A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am J Hum Genet 2004;74:168-175.
6.
Price NT, Jackson VN, Halestrap AP: Cloning and sequencing of four new mammalian monocarboxylate transporter homologues confirms the existence of a transporter family with an ancient past. Biochem J 1998;329:321-328.
7.
Nishimura M, Naito S: Tissue-specific mRNA expression profiles of human solute carrier transporter superfamilies. Drug Metab Pharmacokinet 2008;23:22-44.
8.
Heuer H, Maier MK, Iden S, Mittag J, Friesema EC, Visser TJ, et al: The monocarboxylate transporter 8 linked to human psychomotor retardation is highly expressed in thyroid hormone-sensitive neuron populations. Endocrinology 2005;146:1701-1706.
9.
Chan SY, Franklyn JA, Pemberton HN, Bulmer JN, Visser TJ, McCabe CJ, et al: Monocarboxylate transporter 8 expression in the human placenta: the effects of severe intrauterine growth restriction. J Endocrinol 2006;189:465-471.
10.
Trajkovic-Arsic M, Muller J, Darras VM, Groba C, Lee S, Weih D, et al: Impact of monocarboxylate transporter-8 deficiency on the hypothalamus-pituitary-thyroid axis in mice. Endocrinology 2010;151:5053-5062.
11.
Di Cosmo C, Liao XH, Dumitrescu AM, Philp NJ, Weiss RE, Refetoff S: Mice deficient in MCT8 reveal a mechanism regulating thyroid hormone secretion. J Clin Invest 2010;120:3377-3388.
12.
Trajkovic M, Visser TJ, Darras WM, Friesema ECH, Schlott B, Mittag J, et al: Consequences of MCT8 deficiency for renal transport and metabolism of thyroid hormones in mice Endocrinology 2009;151:802-809.
13.
Friesema EC, Jansen J, Heuer H, Trajkovic M, Bauer K, Visser TJ: Mechanisms of disease: psychomotor retardation and high T3 levels caused by mutations in monocarboxylate transporter 8. Nat Clin Pract Endocrinol Metab 2006;2:512-523.
14.
Bernal J: Thyroid hormone receptors in brain development and function. Nat Clin Pract Endocrinol Metab 2007;3:249-259.
15.
Friesema EC, Visser WE, Visser TJ: Genetics and phenomics of thyroid hormone transport by MCT8. Mol Cell Endocrinol 2010;322:107-113.
16.
Visser WE, Vrijmoeth P, Visser FE, Arts WF, van Toor H, Visser TJ: Identification, functional analysis, prevalence and treatment of monocarboxylate transporter 8 mutations in a cohort of adult patients with mental retardation. Clin Endocrinol (Oxf) 2013;78:310-315.
17.
Mol JA, Visser TJ: Synthesis and some properties of sulfate esters and sulfamates of iodothyronines. Endocrinology 1985;117:1-7.
18.
Friesema EC, Kuiper GG, Jansen J, Visser TJ, Kester MH: Thyroid hormone transport by the human monocarboxylate transporter 8 and its rate-limiting role in intracellular metabolism. Mol Endocrinol 2006;20:2761-2772.
19.
Kersseboom S, Kremers GJ, Friesema EC, Visser WE, Klootwijk W, Peeters RP, et al: Mutations in MCT8 in patients with Allan-Herndon-Dudley-Syndrome affecting its cellular distribution. Mol Endocrinol 2013;27:801-813.
20.
Friesema EC, Jansen J, Jachtenberg JW, Visser WE, Kester MH, Visser TJ: Effective cellular uptake and efflux of thyroid hormone by human monocarboxylate transporter 10. Mol Endocrinol 2008;22:1357-1369.
21.
Brockmann K, Dumitrescu AM, Best TT, Hanefeld F, Refetoff S: X-linked paroxysmal dyskinesia and severe global retardation caused by defective MCT8 gene. J Neurol 2005;252:663-666.
22.
Holden KR, Zuniga OF, May MM, Su H, Molinero MR, Rogers RC, et al: X-linked MCT8 gene mutations: characterization of the pediatric neurologic phenotype. J Child Neurol 2005;20:852-857.
23.
Jansen J, Friesema EC, Kester MH, Milici C, Reeser M, Gruters A, et al: Functional analysis of monocarboxylate transporter 8 mutations identified in patients with X-linked psychomotor retardation and elevated serum triiodothyronine. J Clin Endocrinol Metab 2007;92:2378-2381.
24.
Herzovich V, Vaiani E, Marino R, Dratler G, Lazzati JM, Tilitzky S, et al: Unexpected peripheral markers of thyroid function in a patient with a novel mutation of the MCT8 thyroid hormone transporter gene. Horm Res 2007;67:1-6.
25.
Namba N, Etani Y, Kitaoka T, Nakamoto Y, Nakacho M, Bessho K, et al: Clinical phenotype and endocrinological investigations in a patient with a mutation in the MCT8 thyroid hormone transporter. Eur J Pediatr 2008;167:785-791.
26.
Zung A, Visser TJ, Uitterlinden AG, Rivadeneira F, Friesema EC: A child with a deletion in the monocarboxylate transporter 8 gene: 7-year follow-up and effects of thyroid hormone treatment. Eur J Endocrinol 2011;165:823-830.
27.
Boccone L, Mariotti S, Dessi V, Pruna D, Meloni A, Loudianos G: Allan-Herndon-Dudley syndrome caused by a novel SLC16A2 gene mutation showing severe neurologic features and unexpectedly low TRH-stimulated serum TSH. Eur J Med Genet 2010;53:392-395.
28.
Kersseboom S, Visser TJ: Tissue-specific effects of mutations in the thyroid hormone transporter MCT8. Arq Bras Endocrinol Metabol 2011;55:1-5.
29.
Verge CF, Konrad D, Cohen M, Di Cosmo C, Dumitrescu AM, Marcinkowski T, et al: Diiodothyropropionic acid in the treatment of MCT8 deficiency. J Clin Endocrinol Metab 2012;97:4515-4523.
30.
Wemeau JL, Pigeyre M, Proust-Lemoine E, d'Herbomez M, Gottrand F, Jansen J, et al: Beneficial effects of propylthiouracil plus L-thyroxine treatment in a patient with a mutation in MCT8. J Clin Endocrinol Metab 2008;93:2084-2088.
31.
Biebermann H, Ambrugger P, Tarnow P, von Moers A, Schweizer U, Grueters A: Extended clinical phenotype, endocrine investigations and functional studies of a loss-of-function mutation A150V in the thyroid hormone specific transporter MCT8. Eur J Endocrinol 2005;153:359-366.
32.
Heuer H, Visser TJ: The pathophysiological consequences of thyroid hormone transporter deficiencies: insights from mouse models. Biochim Biophys Acta 2013;1830:3974-3978.
33.
Kinne A, Roth S, Biebermann H, Kohrle J, Gruters A, Schweizer U: Surface translocation and triiodothyronine uptake of mutant MCT8 proteins are cell type-dependent. J Mol Endocrinol 2009;43:263-271.
34.
Filho HC, Marui S, Manna TD, Brust ES, Radonsky V, Kuperman H, et al: Novel mutation in MCT8 gene in a Brazilian boy with thyroid hormone resistance and severe neurologic abnormalities. Arq Bras Endocrinol Metabol 2011;55:60-66.
35.
Horn S, Kersseboom S, Mayerl S, Muller J, Groba C, Trajkovic-Arsic M, et al: Tetrac can replace thyroid hormone during brain development in mouse mutants deficient in the thyroid hormone transporter MCT8. Endocrinology 2013;154:968-979.
36.
Kersseboom S, Visser TJ: MCT8: from gene to disease and therapeutic approach. Ann Endocrinol (Paris) 2011;72:77-81.
37.
Sijens PE, Rodiger LA, Meiners LC, Lunsing RJ: 1H-magnetic resonance spectroscopy in monocarboxylate transporter 8 gene deficiency. J Clin Endocrinol Metab 2008;93:1854-1859.
38.
Azzolini S, Nosadini M, Balzarin M, Sartori S, Suppiej A, Mardari R, et al: Delayed myelination is not a constant feature of Allan-Herndon-Dudley syndrome: report of a new case and review of the literature. Brain Dev 2014;36:716-720.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.